Skip to content

Author

Ed Reznik

We have 3 of 110 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Random mtDNA mutagenesis maps genotype-phenotype associations across metabolic contexts and lineages

Mitochondrial DNA (mtDNA) mutations cause inherited disease, accumulate with age, and recur in tumors, yet their effects remain unresolved because existing models interrogate one engineered allele at a time. We developed mtDIVE, a random C→T mutagenesis platform for pooled mitochondrial forward genetics in human epithe...

Amir Giladi, Ron Baik, Chih-Yao Chung et al. · 0 citations
Open access Sep 2026

Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency

Cancer genomics studies have implicated combined loss of VHL and TSC1 as sufficient to initiate clear cell renal cell carcinoma (ccRCC) in humans. Here, we engineered a mouse model with kidney-specific deletion of Vhl and Tsc1. VhlF/FTsc1F/FKsp-Cre+mice developed multifocal renal cell carcinomas starting at 7 weeks of...

Jia-Ning Xu, Xiao-Qing Cheng, O. A. Aboud et al. · 0 citations
Open access Sep 2026

Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity

MSK-Tox provides an empirical basis for a new precision safety paradigm for predicting who will be harmed by a therapy on the same principles that guide prediction of therapeutic benefit, and identifies two modes of germline susceptibility to treatment toxicity.

Z. Bakouny, X. Guo, F. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.